| __timestamp | Grifols, S.A. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 660772000 | 10811000 |
| Thursday, January 1, 2015 | 736435000 | 33001000 |
| Friday, January 1, 2016 | 775266000 | 64936000 |
| Sunday, January 1, 2017 | 860348000 | 99909000 |
| Monday, January 1, 2018 | 814775000 | 127724000 |
| Tuesday, January 1, 2019 | 942821000 | 161524000 |
| Wednesday, January 1, 2020 | 985616000 | 182933000 |
| Friday, January 1, 2021 | 1061508000 | 219982000 |
| Saturday, January 1, 2022 | 1190423000 | 278139000 |
| Sunday, January 1, 2023 | 1254234000 | 309799000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Grifols, S.A. and Ultragenyx Pharmaceutical Inc. from 2014 to 2023. Over this period, Grifols, S.A. consistently outpaced Ultragenyx in SG&A spending, reflecting its expansive operational scale. By 2023, Grifols' SG&A expenses surged by approximately 90% from 2014, reaching a peak of €1.25 billion. In contrast, Ultragenyx, a relatively smaller entity, saw its SG&A costs grow nearly 28 times, from €10.8 million in 2014 to €310 million in 2023. This stark contrast highlights Grifols' established market presence and Ultragenyx's rapid growth trajectory. Such insights are invaluable for investors and stakeholders aiming to navigate the competitive landscape of the pharmaceutical sector.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.